James S. Park

James S. Park

Auto-generated profile, based on publicly available information

James S. Park

NYU Langone Health, New York, NY, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PGPeter Goldstraw
Peter Goldstraw
KCKari Chansky
Kari Chansky
JCJohn Crowley
John Crowley
RRRamon Rami-Porta
Ramon Rami-Porta
HAHisao Asamura
Hisao Asamura
KYK. Yokoi
K. Yokoi

1 May 2016 in Annals of Surgery
Verified
Journal Article
Closed access
JLJeong-Hoon Lee
Jeong-Hoon Lee
YCYuri Cho
Yuri Cho
HKHwi Young Kim
Hwi Young Kim
ECEun Ju Cho
Eun Ju Cho
DLDong Hyeon Lee
Dong Hyeon Lee
JYJung-Hwan Yoon
Jung-Hwan Yoon
Objective: To develop and validate a model to predict tumor recurrence after living donor liver transplantation (LDLT) (MoRAL) for hepatocellular carcinoma (HCC) beyond the Milan criteria (MC). Background: Some subgroups of HCC exceeding the MC experience substantial benefit from LDLT. Methods: This multicenter study included a total of 566 consecutive patients who underwent LDLT in Korea: the beyond-MC cohort (n = 205, the derivation [n = 92] and validation [n = 113] sets) and the within-MC cohort (n = 361). The primary endpoint was time-to-recurrence. Results: Using multivariate Cox proportional hazard model, we derived the MoRAL score using serum levels of protein induced by vitamin K absence-II and alpha-fetoprotein, which provided a good discriminant function on time-to-recurrence (concordance index = 0.88). Concordance index was maintained similarly on both internal and external validations (mean 0.87 and 0.84, respectively). At cut off of 314.8 (75th percentile value), a low MoRAL score (≤314.8) was associated with significantly longer recurrence-free (versus > 314.8, HR = 5.29, P < 0.001) and overall survivals (HR = 2.59, P = 0.001) in the beyond-MC cohort. The 5-year recurrence-free and overall survival rates of beyond-MC patients with a low MoRAL score were as high as 66.3% and 82.6%, respectively. The within-MC patients with a high MoRAL score showed a higher risk of recurrence than beyond-MC patients with a low MoRAL score (HR = 2.56, P = 0.035). The MoRAL score was significantly correlated with explant histology. Conclusions: This new model using protein induced by vitamin K absence-II and alpha-fetoprotein provides refined prognostication. Among beyond-MC HCC patients, those with a MoRAL score ≤314.8 and without extrahepatic metastasis might be potential candidates for LDLT.

1 January 2020 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
CZChenyang Zhan
Chenyang Zhan
DRDavid Ruohoniemi
David Ruohoniemi
KSKrishna P. Shanbhogue
Krishna P. Shanbhogue
JWJason Wei
Jason Wei
TWTheodore H. Welling
Theodore H. Welling
RHRyan M. Hickey
Ryan M. Hickey

1 November 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
JVJohannes Vermehren
Johannes Vermehren
JPJames S. Park
James S. Park
IJIra M. Jacobson
Ira M. Jacobson
SZStefan Zeuzem
Stefan Zeuzem

1 March 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
CFCatherine T. Frenette
Catherine T. Frenette
GMGiuseppe Morelli
Giuseppe Morelli
MSMitchell L. Shiffman
Mitchell L. Shiffman
RFR. Todd Frederick
R. Todd Frederick
RRRaymond A. Rubin
Raymond A. Rubin
DHDavid T. Hagerty
David T. Hagerty
Caspase-mediated apoptosis and inflammation contribute to progression of liver disease. Emricasan is a pan-caspase inhibitor that reduced serum markers of apoptosis and liver inflammation in patients with hepatitis C and non-alcoholic steatohepatitis (NASH). We performed a multicenter study of 86 patients with cirrhosis (Child-Pugh class A or B; mean score, 6.9; 38% with alcohol-associated cirrhosis, 29% with HCV-associated cirrhosis, and 23% with NASH) and model for end-stage liver disease (MELD) scores of 11-18 (mean, 12.8). Patients were randomly assigned to groups given placebo (N = 42) or Emricasan (25 mg, N = 44), twice daily for 3 months; subjects then received open-label Emricasan (25 mg) twice-daily for 3 months. The primary endpoint was the change from baseline in serum levels of cleaved keratin 18 (CK-18) at month 3. Seventy-four patients completed the 3-month study period (40 given Emricasan and 34 given placebo); 69 patients received open-label Emricasan for 3 months afterward. At the 3-month timepoint, Emricasan significantly reduced mean MELD (P = .003) and Child-Pugh (P = .003) scores in subjects with high MELD scores (15 or more), compared with placebo, with significant reductions in INR (95% CI, -0.2882 to -0.0866) and total bilirubin (95% CI, -1.5069 to -0.0823) vs placebo. There were no significant differences between Emricasan and placebo groups in mean MELD (P = .466) or Child-Pugh (P = .124) scores overall at 3 months compared to placebo. Of patients with high MELD scores, 6/9 given Emricasan (67%) had a reduction of 2 points or more at month 3, compared with 2/10 given placebo (20%). Serum levels of full-length CK-18 (P = .02) and caspase 3/7 (P < .001), but not cleaved CK-18 (P = .092), decreased significantly at 3 months in the Emricasan vs placebo group. Emricasan was well tolerated, and adverse events were balanced between groups. Emricasan's effects were generally maintained or increased after 6 months of treatment. In a randomized trial of patients with cirrhosis, we found 3 months treatment with Emricasan to improve liver function, compared with placebo, reducing MELD and Child-Pugh scores, INR, and total bilirubin in patients with MELD scores ≥15. ClinicalTrials.gov no: NCT02230670.

30 July 2016 in Nanomaterials
Verified
Journal Article
Open access
PDF file
HOHea Ry Oh
Hea Ry Oh
HJHyun-Young Jo
Hyun-Young Jo
JPJames S. Park
James S. Park
DKDong-Eun Kim
Dong-Eun Kim
JCJe-Yoel Cho
Je-Yoel Cho
KKKeun-Sik Kim
Keun-Sik Kim
The combination of therapeutic nucleic acids and chemotherapeutic drugs has shown great promise for cancer therapy. In this study, asialoglycoprotein receptors (ASGPR) targeting-ligand-based liposomes were tested to determine whether they can co-deliver vimentin siRNA and doxorubicin to hepatocellular carcinoma (HCC) selectively. To achieve this goal, we developed an ASGPR receptor targeted co-delivery system called gal-doxorubicin/vimentin siRNA liposome (Gal-DOX/siRNA-L). The Gal-DOX/siRNA-L was created via electrostatic interaction of galactose linked-cationic liposomal doxorubicin (Gal-DOX-L) on vimentin siRNA. Previous studies have shown that Gal-DOX/siRNA-L inhibited tumor growth by combined effect of DOX and vimentin siRNA than single delivery of either DOX or vimentin siRNA. These Gal-DOX/siRNA-Ls showed stronger affinity to human hepatocellular carcinoma cells (Huh7) than other cells (lung epithelial carcinoma, A549). These liposomes also have demonstrated that novel hepatic drug/gene delivery systems composed of cationic lipid (DMKE: O,O’-dimyristyl-N-lysyl glutamate), cholesterol, galactosylated ceramide, POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), and PEG2000-DSPE (distearoyl phosphatidyl ethanolamine) at 2:1:1:1:0.2 (moral ratios) can be used as an effective drug/gene carrier specifically targeting the liver in vivo. These results suggest that Gal-DOX-siRNA-L could effectively target tumor cells, enhance transfection efficacy and subsequently achieve the co-delivery of DOX and siRNA, demonstrating great potential for synergistic anti-tumor therapy.